Biomarker for predicting neoadjuvant chemotherapy curative effect of breast cancer and application of biomarker

Abstract

The invention discloses a biomarker for predicting neoadjuvant chemotherapy curative effect of breast cancer and application of the biomarker. The biomarker for predicting neoadjuvant chemotherapy curative effect of breast cancer is a long non-coding RNA and has a sequence shown in SEQ ID NO:1 or has a corresponding DNA sequence. The biomarker can be used for preparing a kit having one or more than one of functions of prediction of neoadjuvant chemotherapy curative effect of breast cancer, clinical diagnosis, drug screening and treatment assessment. The kit is an RT-qPCR kit or a sequencing kit for quantitatively or qualitatively detecting the long non-coding RNA. The application of the biomarker for predicting the neoadjuvant chemotherapy curative effect of breast cancer is clear, the difference (P is less than 0.05) of the biomarker in pCR group and NpCR group fresh breast cancer tissues is displayed, the expression in the NpCR group fresh breast cancer tissues is obviously higher than that in the pCR group, the biomarker can be used for predicting the neoadjuvant chemotherapy curative effect, and the blindness of the neoadjuvant chemotherapy is avoided.

Description

technical field [0001] The invention belongs to the fields of biotechnology and medicine, and relates to a biomarker for predicting the curative effect of neoadjuvant chemotherapy for breast cancer and its application. Background technique [0002] Breast cancer is one of the most common malignant tumors in women, accounting for 7-10% of all kinds of malignant tumors in the whole body, ranking first in the incidence of malignant tumors in women. Neoadjuvant chemotherapy for breast cancer, also known as preoperative chemotherapy or initial chemotherapy, is essentially adjuvant chemotherapy, but its possible mechanism of action is different from general postoperative adjuvant chemotherapy. It refers to systemic chemotherapy for non-metastatic tumors before local treatment. Sexual and systemic cytotoxic drug therapy. At present, many neoadjuvant chemotherapy regimens can not only be used for patients with advanced breast cancer, but also benefit more and more patients with ear...

AI Technical Summary

Problems solved by technology

[0004] Although the clinical application of neoadjuvant chemotherapy has a history of more than 30 years and has made great progress in recent years, with the deepening of research, many Problems and shortcomings to be solved urgently: (1) 8%-10% of patients develop disease progression (progression disease, PD) after receiving neoadjuvant chemotherapy, and even lose the opportunity of local treatment

(2) In addition, about 20% of breast cancer patients are not sensitive to neoadjuvant chemotherapy

[0005] MALAT1 gene (metastasis associated in lung denocarcinoma transcript 1) is the human lung adenocarcinoma metastasis-associated transcript sub-1 gene, which was originally studied in the metastasis of human non-small cell lung cancer A new long non-coding RNA (long non-coding RNA, LncRNA) was identified by subtractive hybridization screening. It is located on the human chromosome 11q13 and is about 8 700 bp in length. It lacks a meaningful opening Sexual coding frame, the corresponding protein cannot be translated in vitro. It is generally expressed in human and mouse tissue cells, especially in the nervous system

Images